The Effect of ASTARTE™ on Recurrent Urinary Tract Infection
ConditionRecurrent Urinary Tract Infection
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorHvidovre University Hospital
About this trial
Investigate the effect of dietary supplements/probiotic ASTARTE™ ( L. crispatus, L. rhamnosus, L. jensenii, L. gasseri) on the microbiome composition in the intestine and vagina and thereby a reduction of risk factors for the development of rUTI during 6 months of intervention in women aged 18-40 years. This is measured by the incidence of symptomatic UTI.
Eligibility criteria
Qualifiers
Women 18-40 years of age
Recurrent UTI (2 times UTI within 6 months or > 3 times UTI infection within one year).
The subjects should be informed about the trial protocol.
The subject must be able to follow the protocol, have provided voluntary consent and have signed the declaration of consent.
Disqualifiers
Pregnancy or planning pregnancy
Breastfeeding
Participation in another trial with probiotic the last 30 days.
Hypersensitivity to any ingredient in the study product
Trial design
Treatments tested in this trial
- ASTARTE™ oral capsules
- Placebo oral capsules
Treatment groups
720 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov